- Spirovant

Leading the Revolution in Treating Genetic Lung Diseases

Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. We are the only company advancing programs with both AAV and lentivirus vectors.

Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership

26 Jan , 2021   Press Releases

Spirovant leases its new, expanded headquarters and laboratories in the robust gene and cell therapy epicenter of Philadelphia’s University City and welcomes the appointments of Eric Pastor as Senior Vice President of Technology Development and Operations and Maria Limberis, PhD, as Vice President of Research

Spirovant CEO Joan Lau Selected EY Entrepreneur of The Year® in Greater Philadelphia

13 Oct , 2020   Press Releases

Spirovant Sciences CEO Joan Lau selected to receive the Ernst & Young LLP (EY US) Entrepreneur of The Year 2020 Award in Greater Philadelphia by an independent panel of judges.

Spirovant CEO Joan Lau Selected as a Woman of Distinction by Philadelphia Business Journal

7 Oct , 2020   Press Releases

Spirovant announces that CEO Joan Lau, PhD, has been named a 2020 Woman of Distinction by the Philadelphia Business Journal. The award will be presented in a virtual ceremony on November 12 at 11 am.